Abstract
Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2 proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical association was found between p53 and EGFr expression. Weakly positive associations were found between the expression of c-erbB-2 and p53 and between muscle invasive tumours and increased expression of c-erbB-2. Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing prognosis.
MeSH Terms
Aged
Biomarkers, Tumor/analysis
Carcinoma, Transitional Cell/genetics,pathology
ErbB Receptors/analysis,genetics
Female
Gene Expression
Humans
Male
Mutation
Neoplasm Staging
Proto-Oncogene Proteins/analysis,genetics
Receptor, ErbB-2
Staining and Labeling
Tumor Suppressor Protein p53/analysis,genetics
Urinary Bladder Neoplasms/genetics,pathology
Chemicals
Biomarkers, Tumor
Proto-Oncogene Proteins
Tumor Suppressor Protein p53
ErbB Receptors
Receptor, ErbB-2
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Wright C
University Department of Pathology, Newcastle-upon-Tyne, UK.
Mellon K
Johnston P
Lane D P
Harris A L
Horne C H
Neal D E
References (32)
32 references, click to expand
-
Expression of c-erbB-2 protein product in bladder cancer.
Br J Cancer. 1990 Nov;62(5):764-5
PMID: 1978784
-
T antigen is bound to a host protein in SV40-transformed cells.
Nature. 1979 Mar 15;278(5701):261-3
PMID: 218111
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Science. 1989 May 12;244(4905):707-12
PMID: 2470152
-
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Cancer Res. 1989 Apr 15;49(8):2087-90
PMID: 2564806
-
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
J Virol. 1989 Feb;63(2):739-46
PMID: 2642977
-
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.
Lancet. 1987 Jun 20;1(8547):1398-402
PMID: 2884496
-
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.
Lancet. 1985 Feb 16;1(8425):366-8
PMID: 2857420
-
Mutations in the p53 gene occur in diverse human tumour types.
Nature. 1989 Dec 7;342(6250):705-8
PMID: 2531845
-
Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.
Lancet. 1987 Jul 11;2(8550):69-72
PMID: 2885574
-
Genetic alterations during colorectal-tumor development.
N Engl J Med. 1988 Sep 1;319(9):525-32
PMID: 2841597
-
Mouse p53 inhibits SV40 origin-dependent DNA replication.
Nature. 1987 Oct 1-7;329(6138):458-60
PMID: 2821401
-
Human p53 gene localized to short arm of chromosome 17.
Nature. 1986 Feb 27-Mar 5;319(6056):783-4
PMID: 3005871
-
Oligomerization of oncoprotein p53.
J Virol. 1988 Dec;62(12):4737-44
PMID: 3054153
-
High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.
Mol Cell Biol. 1989 Sep;9(9):3982-91
PMID: 2476668
-
p53: a frequent target for genetic abnormalities in lung cancer.
Science. 1989 Oct 27;246(4929):491-4
PMID: 2554494
-
The p53 proto-oncogene can act as a suppressor of transformation.
Cell. 1989 Jun 30;57(7):1083-93
PMID: 2525423
-
Breast cancer and a proto-oncogene.
BMJ. 1989 Oct 28;299(6707):1061-2
PMID: 2511965
-
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
Science. 1989 Apr 14;244(4901):217-21
PMID: 2649981
-
Expression of the nuclear oncogene p53 in colon tumours.
J Pathol. 1989 Mar;157(3):193-9
PMID: 2926561
-
Allele loss on short arm of chromosome 17 in breast cancers.
Lancet. 1988 Dec 17;2(8625):1384-5
PMID: 2904522
-
Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung.
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9252-6
PMID: 2892196
-
P53 expression in breast cancer.
Int J Cancer. 1988 Feb 15;41(2):178-83
PMID: 3276632
-
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.
Nature. 1984 Dec 13-19;312(5995):649-51
PMID: 6390217
-
p53 and DNA polymerase alpha compete for binding to SV40 T antigen.
Nature. 1987 Oct 1-7;329(6138):456-8
PMID: 3309672
-
The epidermal growth factor receptor and the prognosis of bladder cancer.
Cancer. 1990 Apr 1;65(7):1619-25
PMID: 2311071
-
Expression of epidermal growth factor receptor in breast carcinoma.
J Clin Pathol. 1990 May;43(5):385-9
PMID: 2370306
-
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Oncogene. 1990 Jun;5(6):893-9
PMID: 1694291
-
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
EMBO J. 1990 May;9(5):1595-602
PMID: 1691710
-
Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Lancet. 1990 Mar 24;335(8691):675-9
PMID: 1969059
-
Wild type human p53 is antiproliferative in SV40-transformed hamster cells.
Oncogene. 1990 Jul;5(7):973-80
PMID: 2165234
-
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer.
Cancer Res. 1990 Jan 1;50(1):44-7
PMID: 2293558
-
p53 mutations in colorectal cancer.
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555-9
PMID: 1699228